[ad_1]
Photo: Oxford University Pool
The candidate vaccine developed at the University of Oxford is 70 percent effective in preventing the development of COVID-19 symptoms, according to a new clinical study, according to the BBC.
The candidate vaccine is a collaboration between the Swedish company AstraZeneca and the University of Oxford.
More than 20,000 volunteers participated in the study; half in the UK, half in Brazil. Among the volunteers, 30 corona-positive individuals were vaccinated twice, while 101 infected received a placebo variant.
In 70 percent of the cases, the vaccine was effective in stopping the development of symptoms.
Previously, both Moderna and the group Pfizer and BioNtech have confirmed that their vaccines are about 95 percent effective against the virus.
However, the Oxford vaccine is much cheaper, easier to store and therefore also easier to distribute around the world. It will probably need to be stored cold, but not at freezing temperature, like the RNA vaccines from Pfizer and Moderna.
What we know about the vaccine candidate from the pharmaceutical company Pfizer:
On October 1, the EU Medicines Agency EMA started analyzing the research results to assess whether the vaccine can be approved in the EU / Norway.
The EU alliance, of which Norway is a member, has reserved 300 million doses, with the possibility of expanding by 100 million. The COVAX global alliance is also focused on this vaccine. The United States has ordered at least 300 million doses.
This is also one of the vaccines the UK is targeting.
Photo: DADO RUVIC / REUTERS
The case is being updated.
